Discover how rising inflation impacts Eli Lilly employees and retirees. Learn about the Fed's measures and the forces driving inflation, and what it means for Eli Lilly clients.

Dec 8, 2022 · The Inflation Reduction Act includes wins in patient affordability, but penalizes development of small molecule drugs that are needed in cancer and many other diseases.

Mar 1, 2023 · The change, which Eli Lilly said takes effect immediately, puts the drugmaker in line with a provision in the Inflation Reduction Act, which in January imposed a $35 monthly cap on the...

The companies’ moves, which came in 2023 for Eli Lilly and January 1, 2024 for Novo Nordisk and Sanofi, followed the implementation of provisions from the Inflation Reduction Act (IRA), which both senators voted for and passed by one vote in the Senate, to incentivize drug manufacturers to slash prices.

Mar 1, 2023 · Eli Lilly & Co. said it will slash prices on insulin products by 70% starting in the fourth quarter amid rising federal pressure to reduce the cost of the diabetes drug.

May 9, 2023 · Eli Lilly’s R&D chief is attacking a clause in the Inflation Reduction Act that subjects medicines to different price negotiation timelines.

Jan 2, 2024 · – Today, U.S. Senators Mark R. Warner and Tim Kaine—who serves on the Senate Health, Education, Labor and Pensions Committee—released the following statements applauding Eli Lilly, Novo Nordisk, and Sanofi for officially lowering the cost of their insulin products to $35 per month for most patients.

Jun 30, 2023 · Our detailed analysis of Eli Lilly’s upside post-inflation shock captures trends in the company’s stock during the turbulent market conditions seen over 2022. It compares these trends to...

Sep 1, 2022 · The Inflation Reduction Act has profoundly altered the economics of drug development, halving the value of most small molecule therapies and creating economic incentives that are not aligned with science or the needs of patients, according to David Ricks, chair and CEO of Eli Lilly.

Mar 1, 2023 · The move helps Lilly get a leg up on a $35 insulin cap being rolled out under Democrats’ Inflation Reduction Act—though that provision only pertains to patients on Medicare.